Walleye Capital
XENE icon

Walleye Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Walleye Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,587
Closed -$878K – 5069
2025
Q4 		$878K Buy
+19,587
New +$823K ﹤0.01% 2551
2025
Q1 		– Sell
-221,982
Closed -$8.7M – 5238
2024
Q4 		$8.7M Buy
221,982
+117,022
+111% +$4.84M 0.02% 722
2024
Q3 		$4.13M Buy
+104,960
New +$4.23M 0.01% 1322
2024
Q1 		– Sell
-5,054
Closed -$233K – 5959
2023
Q4 		$233K Sell
5,054
-120,974
-96% -$4.27M ﹤0.01% 3576
2023
Q3 		$4.31M Buy
126,028
+36,324
+40% +$1.36M 0.01% 1144
2023
Q2 		$3.45M Sell
89,704
-15,628
-15% -$621K 0.01% 961
2023
Q1 		$3.77M Buy
105,332
+18,815
+22% +$695K 0.06% 420
2022
Q4 		$3.41M Sell
86,517
-1,454
-2% -$52.9K 0.06% 369
2022
Q3 		$3.18M Sell
87,971
-73,956
-46% -$2.66M 0.06% 348
2022
Q2 		$4.93M Buy
161,927
+7,619
+5% +$230K 0.14% 175
2022
Q1 		$4.72M Buy
154,308
+82,324
+114% +$2.46M 0.13% 173
2021
Q4 		$2.25M Buy
+71,984
New +$2.15M 0.07% 303
2018
Q3 		$101K Buy
+7,647
New +$88.6K 0.05% 257

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's XENE Position: Q1 2026 in Review

Walleye Capital sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 19,587 shares — an estimated $878K sold.

Walleye Capital first reported a position in XENE in Q3 2018 and held it in 13 quarters. The position peaked at $8.7M in Q4 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Walleye Capital reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 19,587 Xenon Pharmaceuticals shares in Q1 2026, an estimated $878K.
  • Walleye Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 13 quarters.
  • Walleye Capital's Xenon Pharmaceuticals position peaked at $8.7M in Q4 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.